蛋白质亚单位
免疫学
病毒学
2019年冠状病毒病(COVID-19)
医学
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
2019-20冠状病毒爆发
生物
传染病(医学专业)
疾病
基因
生物化学
爆发
病理
作者
Eun Kim,Juyeop Shin,Alessandro Ferrari,Shaohua Huang,Eun-Jin An,Donghoon Han,Muhammad S. Khan,Thomas W. Kenniston,Irene Cassaniti,Fausto Baldanti,Dohyeon Jeong,Andrea A. Gambotto
标识
DOI:10.1016/j.intimp.2024.111569
摘要
The COVID-19 pandemic has underscored the pressing need for safe and effective booster vaccines, particularly in considering the emergence of new SARS-CoV-2 variants and addressing vaccine distribution inequalities. Dissolving microneedle array patches (MAP) offer a promising delivery method, enhancing immunogenicity and improving accessibility through the skin’s immune potential. In this study, we evaluated a microneedle array patch-based S1 subunit protein COVID-19 vaccine candidate, which comprised a bivalent formulation targeting the Wuhan and Beta variant alongside a monovalent Delta variant spike proteins in a murine model. Notably, the second boost of homologous bivalent MAP-S1(WU + Beta) induced a 15.7-fold increase in IgG endpoint titer, while the third boost of heterologous MAP-S1RS09Delta yielded a more modest 1.6-fold increase. Importantly, this study demonstrated that the administration of four doses of the MAP vaccine induced robust and long-lasting immune responses, persisting for at least 80 weeks. These immune responses encompassed various IgG isotypes and remained statistically significant for one year. Furthermore, neutralizing antibodies against multiple SARS-CoV-2 variants were generated, with comparable responses observed against the Omicron variant. Overall, these findings emphasize the potential of MAP-based vaccines as a promising strategy to combat the evolving landscape of COVID-19 and to deliver a safe and effective booster vaccine worldwide.
科研通智能强力驱动
Strongly Powered by AbleSci AI